Peptide CDMO Capacity Investment Outlook: Who Is Building What for 2027-2028

The Supply-Demand Equation in Peptide Manufacturing

The global market for contract peptide synthesis services has experienced sustained demand growth driven by the GLP-1 prescribing boom, a maturing peptide therapeutics pipeline with multiple candidates approaching commercialization, and expansion of peptide use into new therapeutic areas including oncology, neurology, and cardiovascular disease.

The demand signal has been clear enough that CDMOs of varying sizes have announced capacity expansions, and the investment community has directed capital toward peptide manufacturing infrastructure through both public company financing and private equity acquisition of manufacturing assets.

Understanding who is building what, and on what timeline, is strategically relevant for biotech companies selecting development partners, for investors evaluating CDMO assets, and for scientists and engineers considering career moves toward the manufacturing sector.

Total GMP peptide manufacturing capacity globally is estimated at approximately 50,000-70,000 kilograms per year of synthetic peptide, a figure that has grown by roughly 20% since 2022. Announced expansion projects would add another 12,000-18,000 kilograms of capacity by 2028 if completed on schedule. Industry veterans note that facility construction and qualification timelines routinely run 12-18 months longer than initial projections.

Major Capacity Expansion Projects

The landscape of announced and in-progress capacity investments includes both brownfield expansions at existing facilities and greenfield construction of dedicated peptide manufacturing sites.

European large-scale expansion: Several European CDMOs with established peptide synthesis operations have announced reactor capacity additions targeting commercial-scale GLP-1 and obesity peptide production. These expansions focus on multi-thousand liter scale synthesis for commercial supply, a significant step up from the kilogram-scale clinical production that most CDMOs have historically operated.

US domestic capacity building: There has been notable investment in US domestic peptide manufacturing, partly driven by biosecurity and supply chain resilience concerns that became prominent after COVID-era disruptions. New facilities are under construction or planning in several US states, with a concentration in the Southeast due to lower construction and operating costs.

Asian CDMO investment: Indian and Korean CDMOs have announced significant peptide synthesis investments, targeting both domestic markets and export to US and EU pharma companies seeking cost-competitive manufacturing. Indian API manufacturers with experience in small molecule production are converting capacity to peptide synthesis as the peptide market grows faster than legacy generics.

Specialty capability investment: A second tier of CDMOs is differentiating on capability rather than scale. Investments in this category include continuous manufacturing systems that reduce cost-per-gram versus batch synthesis for high-volume products, conjugated peptide production capabilities for antibody-drug conjugate linker peptides and PEGylated products, and radiopharmaceutical-grade peptide synthesis for the rapidly growing theranostics market.

Technology Choices Driving Investment Decisions

The capital investment landscape reflects diverging views on which peptide manufacturing technologies will dominate commercially.

Solid-phase vs. liquid-phase synthesis: The majority of current GMP peptide manufacturing uses solid-phase peptide synthesis (SPPS), which is well understood, scalable, and produces the purity profiles that regulatory agencies require. Some CDMOs are investing in liquid-phase synthesis capabilities for specific peptide structures where SPPS yields are poor or costs are prohibitively high at commercial scale.

Continuous manufacturing: The FDA has actively encouraged pharmaceutical manufacturers to adopt continuous manufacturing as a quality improvement and cost reduction strategy. For peptide synthesis, continuous approaches including continuous SPPS and continuous purification chromatography are moving from research into commercial-scale implementation at several facilities. CDMOs that successfully implement continuous manufacturing will have a cost and flexibility advantage for high-volume products.

Biocatalytic synthesis: Enzymatic and biocatalytic approaches to peptide synthesis offer potential advantages in selectivity, stereochemical control, and environmental footprint. Several CDMOs are building biocatalytic synthesis capabilities as a premium service, particularly for complex peptides where chemical synthesis yields are limited by racemization or difficult coupling steps.

Staffing Implications of Capacity Growth

Every announced capacity expansion creates downstream demand for skilled scientific and technical personnel. The staffing implications of the CDMO investment wave are significant and are already affecting labor markets in the manufacturing regions where these facilities are being built.

Peptide synthesis scientists: Chemists with hands-on experience in SPPS, HPLC purification, and lyophilization are in high demand at CDMOs across all geographies. Entry-level demand is strong but mid-career scientists (5-10 years of experience) with GMP operational history are the most constrained resource.

Process engineers: Scale-up from laboratory to commercial GMP production requires process engineers who understand both the chemistry of peptide synthesis and the engineering principles of reactor design, solvent handling, and process analytical technology. This profile is rare and commands premium compensation.

Quality assurance and regulatory affairs specialists: GMP manufacturing facilities require robust quality systems and regulatory affairs support. CDMOs are hiring QA and RA professionals who can support FDA facility inspections, maintain batch record systems, and interface with pharma clients on regulatory submissions.

Manufacturing operations management: Building and running a GMP peptide synthesis facility at commercial scale requires manufacturing operations leaders who can balance safety, quality, cost, and scheduling objectives. Experienced pharmaceutical manufacturing directors are actively recruited as CDMOs ramp up commercial operations.

Competitive Dynamics for Biotech Manufacturing Partners

For biotech companies selecting a CDMO partner for peptide development programs, the expanding capacity landscape creates both opportunity and complexity.

The good news is that increased capacity should eventually moderate the supply tightness that has led to long wait times and elevated pricing for GMP peptide synthesis. The challenge is that not all announced capacity will be brought online on schedule, and CDMOs with the best capabilities and quality track records will continue to attract the most attractive client programs.

Companies with late-stage clinical programs should secure manufacturing commitments well in advance of Phase III initiation, as capacity for commercial-scale synthesis remains the tightest bottleneck. Early engagement with CDMO partners, including tech transfer and process development support agreements, provides optionality that clinical-stage companies should not defer.

---

PeptideStaff covers hiring trends, regulatory developments, and market analysis for the peptide therapeutics industry. Explore our peptide industry staffing resources for more coverage.